Oscotec Inc.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
FDA Grants Orphan Drug Designation to Cevidoplenib for ITP 2024-03-21 20:00
Oscotec/ADEL Initiates First-in-Human Dosing in Ph1 of Anti-MTBR Tau Antibody ADEL-Y01 In Alzheimer's Disease 2024-02-23 21:00
Oscotec/ADEL Announce FDA Clearance of IND Application of ADEL-Y01 for the Treatment of Alzheimer's Disease 2023-09-14 20:00
Oscotec Announces Topline Results for Phase 2 Trial of Cevidoplenib 2023-02-24 22:00
1